On November 2, 2025, the Ministry of Industry and Information Technology (MIIT) and the National Medical Products Administration (NMPA) jointly released the shortlist of selected entities for the Innovation Challenge for Biomedical Materials (Second cohort) (Document No. MIIT-LYH [2025] 422). Imeik Technology Development Co., Ltd. was honored as a designated company for the biomedical materials innovation challenge, undertaking the research and development project in the field of "Inorganic Non-Metallic Materials—Collagen/Calcium Phosphate Composites." This selection represents both authoritative national recognition of the company's technological capabilities and reflects the industry's expectations for breakthroughs in advanced medical materials to meet the people's health needs.
The Innovation Challenge for Biomedical Materials is a major national innovation project jointly organized by the MIIT and NMPA. Its core objective is to focus on bottleneck technological challenges in the field of biomedical materials, select the most capable innovation entities to undertake focused research and development, and achieve breakthroughs in the industrialization of high-end medical materials. Through a multi-stage standardized evaluation process, including provincial and municipal recommendations, nationwide shortlisting, on-site presentations, and expert reviews, Imeik responded to the requirements at each stage with solid technical reserves and a rigorous project proposal, and was awarded the project.
As China's earliest innovator in self-developed biomedical materials for medical aesthetics, Imeik uphelds the purpose of "cultivating beautiful look, beautiful mind and beautiful lives by using technology." For over two decades, the company has consistently regarded innovation in biomedical materials as its core competitive strength, continuously leading industry technology upgrade. This selection not only validates the maturity of the company’s forward-looking R&D pipelines and core technology platforms, but also signifies that Imeik’s capabilities in material innovation, R&D, and industrialization practices have received high-level recognition at the national level.
Imeik has successfully established a biomedical materials technology platform centered on hyaluronic acid, polylactic acid, polyvinyl alcohol, poly(p-dioxanone), and other core materials, achieving large-scale production and industrial application in high-value medical device products. The company holds 12 Class III Medical Device Registration Certificates, with multiple products filling domestic gaps.
Going forward, Imeik will take this tackling as an opportunity to continuously strengthen R&D investment, further improve the biomedical materials technology platform, and use material technology as a bridge to steadily expand its broader health sector presence.
According to the plan, during the project tackling period, the R&D team will, through in-depth analysis of the multi-level ordered structures of natural tissues, adopt a unique bio-inspired fabrication concept to achieve precise control of material structures from the nanoscale to the macroscopic level, laying a theoretical foundation and providing technical support for the development of next-generation tissue repair products.
